3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms 3T Study
Most Recent Events
- 30 Jul 2024 Planned primary completion date changed from 30 May 2024 to 30 May 2025.
- 30 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Oct 2023 Planned initiation date changed from 20 Oct 2023 to 30 Nov 2023.